Degarelix Dosing and Monitoring for Advanced Prostate Cancer
Administer degarelix as a 240 mg subcutaneous loading dose followed by 80 mg subcutaneous maintenance doses every 28 days, with testosterone monitoring at baseline, day 28, and then every 3-6 months to confirm castration levels ≤50 ng/dL. 1
Dosing Regimen
Initial Loading Dose
- 240 mg subcutaneously administered as two 120 mg injections at a concentration of 40 mg/mL
- Given on Day 0 (treatment initiation)
Maintenance Dosing
- 80 mg subcutaneously administered as a single injection at a concentration of 20 mg/mL
- Given every 28 days starting on Day 28
- Continue monthly until disease progression or unacceptable toxicity 1
The FDA-approved dosing is based on phase III data demonstrating a 97.2% castration rate (testosterone ≤50 ng/dL) maintained from day 28 through day 364 1, 2. The 160 mg maintenance dose showed similar efficacy but is not FDA-approved and offers no additional benefit 1.
Mechanism and Pharmacodynamics
Degarelix is a GnRH receptor antagonist that immediately suppresses testosterone without causing the initial testosterone surge seen with GnRH agonists 1. This is a critical advantage—96% of patients achieve castration levels within 3 days, compared to 0% with leuprolide at the same timepoint 2. The drug forms a subcutaneous depot with a terminal half-life of approximately 53 days, allowing for sustained testosterone suppression 1.
Monitoring Parameters
Testosterone Levels
- Baseline: Obtain serum testosterone before first dose
- Day 28: Confirm achievement of castration level (≤50 ng/dL)
- Ongoing: Every 3-6 months to ensure maintained suppression 1
PSA Monitoring
- Baseline PSA
- Monthly for first 3 months (degarelix achieves significantly faster PSA suppression than GnRH agonists—median PSA levels at 14 and 28 days were significantly lower, P<0.001) 2
- Every 3 months thereafter to assess disease response
Additional Monitoring
- Liver function tests periodically (transaminase elevations reported) 3
- Cardiovascular risk assessment, particularly in patients with pre-existing cardiovascular disease 4
- Bone density monitoring per standard ADT guidelines
Role in Treatment Algorithm
Degarelix represents one of four separate standards of care for androgen deprivation therapy in noncastrate metastatic prostate cancer, alongside GnRH agonists, when combined with intensification agents (docetaxel, abiraterone, enzalutamide, or apalutamide) 5.
Key clinical scenarios favoring degarelix:
- Patients requiring rapid testosterone suppression (e.g., spinal cord compression risk, severe bone pain)
- Patients where testosterone flare could be problematic
- Patients with cardiovascular disease (very uncertain evidence, but one small trial suggested benefit) 4
Safety Profile and Common Pitfalls
Expected Adverse Events
- Injection site reactions (40%): Most common adverse event, typically mild-to-moderate erythema, swelling, or induration at injection site 2
- Hot flushes: Similar frequency to GnRH agonists
- Weight gain: Expected effect of testosterone suppression
- Injection site pain: Significantly increased compared to intramuscular GnRH agonists (RR 15.68) 4
Critical Pitfall to Avoid
Do not use antiandrogen co-treatment with degarelix—unlike GnRH agonists, degarelix causes no testosterone flare, so antiandrogen "flare protection" is unnecessary and adds toxicity without benefit 2.
Cardiovascular Considerations
The cardiovascular safety profile appears favorable in one small trial of high-risk patients (RR 0.15 for cardiovascular events), but this evidence is very uncertain and should not drive treatment decisions 4. Standard cardiovascular risk management for all ADT patients remains essential.
Administration Technique
- Administer subcutaneously in the abdominal region
- Rotate injection sites
- Loading dose requires two separate 120 mg injections
- Maintenance dose is a single 80 mg injection
- Concentration matters: loading dose at 40 mg/mL, maintenance at 20 mg/mL 1
Treatment Duration
Continue degarelix monthly until documented disease progression or unacceptable toxicity. Studies demonstrate maintained efficacy for up to 5 years of continuous treatment 6.